Trial Profile
Phase II Study of Sorafenib (Bay 43-9006) and Docetaxel in Metastatic Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Sorafenib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 25 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 25 Feb 2009 Official Title amended as reported by ClinicalTrials.gov.